Nov 23, 2023 Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

happy

Patrick Boland, MD, medical oncologist, Gastrointestinal Oncology team, Rutgers Cancer Institute of New Jersey, RWJBarnabas Health, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer (CRC). Watch more at onclive.com.

onclive.com